Nyxoah to Release Financial Results for Q1 2025
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), a pioneering medical technology company, is set to unveil its financial results for the first quarter of 2025 on May 14, 2025. The company focuses on innovative treatment solutions for Obstructive Sleep Apnea (OSA), a condition affecting many individuals worldwide. A conference call will be held at 2:00 PM CET / 8:00 AM ET, during which company management will discuss these results in detail.
Conference Call Details
For interested participants, the conference call will be accessible via Nyxoah's Investor Relations page. The company recommends that participants who wish to ask questions register in advance using a designated link. This allows attendees to join the live discussion, enhancing engagement and interaction with the management team. To ensure a seamless experience, it’s advisable to register at least 10 minutes before the call begins.
About Nyxoah
Nyxoah is committed to delivering advanced therapeutic options for those suffering from Obstructive Sleep Apnea. Their flagship product, the Genio® system, is a groundbreaking, leadless, and battery-free neurostimulation therapy targeted at individuals who face challenges with traditional treatments. Given that OSA is recognized as the most prevalent form of sleep-disordered breathing, Nyxoah is dedicated to drastically improving patients' quality of life.
Technological Innovations
The Genio® system employs neuromodulation technology that has already received acclaim with its European CE Mark as of 2019. Following this, Nyxoah successfully executed two IPOs—initially on Euronext Brussels and subsequently on NASDAQ, showcasing its robust growth trajectory. Recent studies have further validated the Genio® system's effectiveness in treating patients with Complete Concentric Collapse (CCC), expanding its market potential significantly.
Positive Outcomes from Clinical Studies
Notably, the BETTER SLEEP study yielded promising results, and a recent pivotal DREAM IDE study also confirmed the system's efficacy. These milestones underscore Nyxoah’s drive to innovate and enhance patient treatments across diverse scenarios, reinforcing the company’s commitment to improving health outcomes.
Future Directions
As Nyxoah sets its sights on advancing its product offerings, the company is also focused on obtaining necessary approvals, including from the FDA, to broaden its reach in the U.S. market. This strategic expansion is vital, given the increasing awareness and diagnosis of OSA, which correlates with various health issues, including heightened mortality risk.
Frequently Asked Questions
How can I join the Nyxoah Q1 2025 financial call?
To join the call, visit Nyxoah's Investor Relations page where the details for registration are provided. Make sure to register at least 10 minutes before the event.
What is the Genio® system?
The Genio® system is Nyxoah’s lead product designed for patients with Obstructive Sleep Apnea, utilizing a unique leadless and battery-free neurostimulation approach.
What recent studies have supported the Genio® system?
The system has shown positive results in both the BLAST OSA and BETTER SLEEP studies, demonstrating its effectiveness and suitability for various patient profiles.
When is the financial results announcement for Q1 2025?
The announcement will take place on May 14, 2025, and will be followed by a conference call discussing the results.
Can I ask questions during the conference call?
Yes, participants can submit questions by registering in advance via the designated link provided in the conference call announcement.
